Cytochrome P450 content and activities are increased in the kidneys of spontaneously hypertensive rats (SHR) as compared with those of normotensive, Wistar-Kyoto (WKY), control rats during the period of rapid elevation of blood pressure.
abdominal pain and paresis and frequently accompanied by hypertension (1) . The exact pathogenesis of hypertension in an acute porphyric attack is not well understood. Currently, heme arginate is used in Europe in the treatment of acute attacks of AIP so as to normalize the levels of "free" heme and thereby decrease the induced levels of S-aminolevulinic acid synthetase, an enzyme under negative feedback control by unbound or "free" heme (2-6). Kordac and co-workers (7) observed rapid normalization of hypertension after administration of heme arginate to patients with attacks ofAIP. This observation prompted us to study the effect of this compound on blood pressure in spontaneously hypertensive rats (SHR), the animal model of human essential hypertension (8) . In this model, blood pressure increases most rapidly from 100 to 170 mm Hg between 5 and 13 wk of age, whereas in the age-matched normotensive rat systolic blood pressure rarely exceeds 130 mm Hg. Elevation of blood pressure in the SHR can be partially suppressed by a renal transplant from a normotensive donor, suggesting that abnormalities in kidney function are responsible, in part, for the elevation of blood pressure in SHR (9) . These abnormalities consist of reduced excretion of sodium and water, decreased renal blood flow, and decreased glomerular filtration rate. The resetting of renal function appears to occur early in the SHR and may be necessary for the development of hypertension (10) . For example, fractional sodium and water excretion were significantly less in the SHR when compared with age-matched Wistar-Kyoto rats (WKY), a difference which disappeared by 8 wk of age (1 1) .
An increase in hepatic and renal cytochrome P450 content and its related drug metabolizing enzyme systems has been demonstrated in SHR (12, 13 26 .7 mg of L-arginine in 1 ml ofsaline. Rats treated with Zn-2,4-deuteroporphyrin IX bis glycol (ZnDPBG; Porphyrin Products, Logan, UT) were injected subcutaneously with 0.2 ml of a freshly prepared ZnDPBG solution. The control SHR and WKY were injected with saline. Blood pressure from the tail was measured without anesthesia using a plethysmograph before and 23 h after the last injection.
Control and treated animals were killed in pairs 5, 7, and 24 h after the last heme arginate administration. One kidney from each rat and parts of liver were immediately frozen in liquid nitrogen for RNA extraction. The remaining control and treated animals were killed 24 h after heme arginate treatment. Livers and kidney were perfused with cold saline. Groups of control and treated animals were kept for study ofthe long-term effect on blood pressure after heme arginate treatment at age 45-48 d; blood pressure was measured once a week from 7 to 13 wk of age.
Cytochrome P450 content. Livers were immediately perfused with cold saline, sliced, and homogenized (4 ml/g wet weight) in 10 mM Tris buffer, pH 7.5, containing 0.25 M sucrose. The tissue homogenates were centrifuged at 27,000 g for 20 min at 4°C. The supernatant was centrifuged at 105,000 g for I h at 4°C, and the resulting microsomal pellet was resuspended in 0.1 M potassium phosphate buffer, pH 7.6. Protein concentration was determined by the method of Lowry et al. (19) with bovine serum albumin (fraction V) as a standard. Cytochrome P450 content was measured from the reduced carbon monoxide difference spectrum using sodium dithionite as the reducing agent. The absorbance difference between 450 and 490 nm was monitored and cytochrome P450 content calculated using a molar extinction coefficient of 91 mM-' cm-' (20) .
Cytochrome P450 AA metabolism. AA metabolism was measured as described previously (13 Heme oxygenase mRNA levels in rat liver and kidney. The levels of heme oxygenase mRNA in rat liver and kidney were determined by Northern blot analysis of total RNA using cDNA for rat heme oxygenase. The probe used in this study was the 883 base-pair EcoRlHind III fragment of pRHO 1, a plasmid containing full-length cDNA for rat spleen heme oxygenase (23, 24) . This fragment contains the structural gene for all but the first 29 amino acid residues of the enzyme and has been shown to cross-react with heme oxygenase mRNA in rat liver and glioma cells (25) . The 
Results
Effect ofheme arginate on systolic blood pressure. In preliminary experiments we determined the dose-response relationship of hemin, L-arginine, and heme arginate with respect to blood pressure. Heme arginate, as well as hemin and L-arginine, were given for 4 d consecutively as is done with heme arginate in acute hepatic porphyric patients (3). As seen in Fig.  1 , at the three doses used all substances significantly reduced blood pressure of 7-wk-old SHR. Although the effect of both L-arginine and hemin seems to plateau at 15 mg/kg, the synergism ofhemin and L-arginine in the form ofheme arginate was evident at both 15 and 30 mg/kg body weight/day (Fig. 1) . We therefore performed all the experiments described in these studies on rats treated with heme arginate or related compounds at a dose of 15 mg/kg body weight for 4 121 .0±2.1 mm Hg for control and treated rats, n = 8). The effect of heme arginate could be detected after the first day of its administration. The maximal effect was achieved by the fourth day of treatment, but blood pressure started to increase after cessation of heme arginate administration (Fig. 2) . Furthermore, the heme arginate effect on blood pressure was also evident in 22-wk-old SHR. Administration of heme arginate at 15 and 30 mg/kg body weight for 4 (Table I) . Interestingly, when 7-wk-old SHR were treated with heme arginate and an inhibitor of heme oxygenase, ZnDPBG (27) , blood pressure decreased by only 14 mm Hg and was significantly higher than that of the heme arginate-treated SHR. The heme oxygenase inhibitor alone did not have any effect on blood pressure (Table I) .
Effect of heme arginate on heme oxygenase activity. The last observation raised the possibility that the effect of heme arginate is in part associated with heme oxygenase activity as recently demonstrated for SnCl2 (16 treatment, whereas renal activity remained induced. The specificity of heme arginate as an inducer of heme oxygenase was further demonstrated by Northern blot analysis using rat cDNA heme oxygenase. As seen in Fig. 4 , Northern blot analysis of heme oxygenase clearly demonstrated that heme oxygenase mRNA increased drastically as a result of administration of heme arginate. The maximum induction of heme oxygenase mRNA was noticed between 5 and 7 h after the last injection of heme arginate in both kidney and liver (Fig. 4) . In both kidney and liver the level of heme oxygenase mRNA returned to control levels 24 hrs after the last injection of heme arginate (Fig. 4, arginate (Figs. 5 and 6 ), however, its lowering effect on blood pressure (Table I) (16) . We, therefore, studied the effect of heme arginate on cytochrome P450 levels and its dependent AA oxidations. The basal level of cytochrome P450 in both kidney and liver of 7-wk-old SHR is significantly higher than that in age-matched WKY (references 13 and 14 and Fig. 7 ). Interestingly, the basal level of hepatic heme oxygenase in WKY is 50% higher than that in SHR (Fig.  7) . When SHR were treated with heme arginate or hemin alone at a dose of 15 mg/kg, a decrease in hepatic and renal cytochrome P450 level was observed (Figs. 5 and 6 ). The reduction in renal cytochrome P450 was associated with a reduction in w/w-I hydroxylation of AA. As seen in Fig. 8 HETE. Both metabolites exhibit biological activities that promote hypertension, i.e., vasoconstriction and Na+-K+-ATPase stimulation. The effect of both hemin and heme arginate was dose dependent. At doses of 9 mg/kg body weight both substances caused inhibition of w/w-l hydroxylation of 10% and 12% for hemin and heme arginate, respectively (data not shown).
Discussion
Increased levels and activities of the cytochrome P450 system have been documented in liver and kidney ofSHR, the animal model for human essential hypertension (12, 13) . AA is an endogenous substrate of the cytochrome P450 system and the formation of its oxidative metabolites, mainly 19-HETE and 
